Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • News
    • News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
  • Toggle search form

[Disclosure] Celltrion (068270) Logs Preliminary Separate Q4 Revenue of KRW 1.06T, Increasing 235.96% YoY

Posted on February 25, 2025July 16, 2026 By K-STOCK Editor No Comments on [Disclosure] Celltrion (068270) Logs Preliminary Separate Q4 Revenue of KRW 1.06T, Increasing 235.96% YoY

Source: Financial Supervisory Service Dart System / 2025-02-25

Disclosure Type: Preliminary Earnings Release (Separate)

💡 3-Second Summary

Celltrion has released its preliminary Q4 2024 separate financial results, reporting revenue of approximately KRW 1.06T, up 235.96% year-on-year, and bringing its cumulative separate annual revenue to KRW 3.71T.

📊 1. [Key Disclosure Content & Major Figures Summary]

  • Q4 2024 Preliminary Separate Financial Performance (Quarterly):
    • Revenue: KRW 1057,839M (approx. KRW 1.06T) / Up 1.72% QoQ, Up 235.96% YoY
    • Operating Profit: KRW 407,521M (approx. KRW 407.5B) / Down 11.73% QoQ, Up 1476.91% YoY
    • Income Before Income Taxes: KRW 485,588M (approx. KRW 485.6B) / Up 12.72% QoQ, Up 6804.42% YoY
    • Net Profit: KRW 378,578M (approx. KRW 378.6B) / Up 18.04% QoQ, Up 1223.19% YoY
  • FY 2024 Cumulative Separate Preliminary Performance (Annual):
    • Cumulative Revenue: KRW 3,709,214M (approx. KRW 3.71T) / Up 97.99% compared to previous year (KRW 1,873,430M)
    • Cumulative Operating Profit: KRW 1,211,014M (approx. KRW 1.21T) / Up 89.67% compared to previous year (KRW 638,489M)
    • Cumulative Income Before Income Taxes: KRW 1,271,853M (approx. KRW 1.27T) / Up 86.36% compared to previous year (KRW 682,473M)
    • Cumulative Net Profit: KRW 1,004,841M (approx. KRW 1.00T) / Up 78.39% compared to previous year (KRW 563,268M)
  • Administrative and Explanatory Notes:
    • These preliminary figures are based on Celltrion’s separate financial statements.
    • These figures represent the company’s internal preliminary calculations and may be modified depending on the external auditor’s final audit results.
    • No specific reasons for the performance changes were provided in this regulatory filing.

📈 2. [Expert Perspective: What This Means for Investors]

  • Growth in Separate Revenue metrics: Celltrion’s separate Q4 preliminary revenue reached approximately KRW 1.06T, showing an increase of 1.72% QoQ and 235.96% YoY. Annual separate revenue accumulated to approximately KRW 3.71T, growing by 97.99% compared to the prior fiscal year.
  • Diverging Short-term vs. Annual Trends: Preliminary separate operating profit for the fourth quarter was approximately KRW 407.5B, marking an expansion of 1476.91% YoY, but reflecting an 11.73% contraction compared to the prior quarter. Annually, separate operating profit reached KRW 1.21T, showing an 89.67% increase compared to the previous year.
  • Lack of Explanatory Footnotes: This voluntary disclosure is purely numerical and does not detail the operational factors or transactional drivers behind the reported quarterly and cumulative separate performance changes.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion has disclosed its preliminary separate earnings for Q4 2024. The filing provides numerical preliminary data showing quarterly separate revenue of approximately KRW 1.06T and cumulative annual separate revenue of approximately KRW 3.71T, conveying the company’s separate financial performance to the market.

The primary check point for investors moving forward is the formal verification of these separate metrics against the audited, finalized financial results. Because these figures are generated through internal preliminary calculations before the external audit process is concluded, investors must cross-reference them with the upcoming separate financial statements in the official annual audit report.

Additionally, while cumulative separate revenues and operating profits showed growth, the specific operational drivers behind these variations are not outlined in the disclosure. Investors are advised to objectively monitor subsequent audited reports and annual filings to review verified separate financial details once the complete annual statements are published.

📢 Disclaimer & Sources

Source: This content was structured and newly generated based on official disclosure data submitted to the Financial Supervisory Service (DART) of South Korea.

Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.

Inquiries: For compliance queries or copyright requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Celltrion (068270) Decides to Convene AGM on March 25, 2025; Proposes Re-election of Chairman Seo Jung-jin as Inside Director
Next Post: [Disclosure] Celltrion (068270) Reports FY2024 Consolidated Revenue of KRW 3.56T, Up 63.45% YoY; Operating Profit Declines 24.48% on Merger-Related Costs

Related Posts

[Disclosure] Jusung Engineering (036930) to Host Large-Scale IR Meeting in Yeouido on July 5 to Explain Corporate Governance Restructuring Strategy Semiconductors
[Disclosure] Hanwha Aerospace (012450) Submits Amended Disclosure to Reveal KRW 436.6B Defense Supply Contract Details for Estonia Chunmoo Project Following Expiration of Confidentiality Omission Disclosures
[Disclosure] Celltrion (068270) Reduces Outstanding Shares by 268,385 Through Share Cancellation, Change Listing Effective April 30 Disclosures
[Disclosure] Samsung Biologics (207940) Stock Futures and Options Post Temporary Suspension, Trading Resumed at 09:30 Disclosures
[Disclosure] Celltrion (068270) Stock Futures & Options Market Measures Scheduled Following Bonus Issue (Effective June 9) Disclosures
[Disclosure] Celltrion Amends Translation Procedure for Hong Kong Investor Relations Conference (068270) Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Alteogen (196170) Establishes August 6 as Record Date for Bonus Issue Share AllotmentJuly 16, 2026
  • [Disclosure] Alteogen (196170) Announces Trading Suspension and Resumption Schedule for Stock Futures and OptionsJuly 16, 2026
  • [Disclosure] Alteogen (196170) Temporarily Suspends Plans for Relisting on the KOSPI MarketJuly 16, 2026
  • [Disclosure] Alteogen (196170) Announces Temporary Trading Suspension on July 16 Due to Bonus Issue DecisionJuly 16, 2026
  • [Disclosure] Alteogen (196170) Decides on Bonus Issue of 0.3 Shares per 1 Common and Preferred ShareJuly 16, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme